CONTROLLED TRIAL OF ALENDRONATE FOR THE TREATMENT OF CHILDHOOD AND ADOLESCENT

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是比较阿仑磷酸钠(Fosamax Merk&Co.)使用安慰剂和标准护理(钙和维生素D)治疗8-21岁儿童因服用类固醇而导致的骨瘦症。阿伦磷酸钠确实可以改善患有骨质疏松症的成年人的骨骼强度和健康。因此，一些儿科医生目前正在使用阿伦磷酸钠来治疗骨质疏松症的年轻人。然而，没有研究证明阿伦磷酸钠对儿童和青少年是否有效，以及对年轻人有什么副作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the drug alendronate (FOSAMAX Merk &Co., Inc.) with a placebo and the standard of care (calcium and vitamin D) in treating children 8-21 years of age with thin bones caused by taking steroids. Alendronate does improve the strenth and health of bones in adults with osteoporosis. As a result, some pediatricians are currently using alendronate to treat young people with weak bones.However, there are no studies proving whether or not alendronate works in children and adolencents and what the side effects are in younger people.